ACP5 and cardiovascular disorder: In contrast, TRACP-5a has been identified as a biomarker for cancer cachexia, metastatic breast cancer progression, end-stage renal disease, rheumatoid arthritis, and sarcoidosis [6–10] and as a potential risk factor for cardiovascular disease [11].